We and others have previously demonstrated that the endothelium is a primary target of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and L-arginine has been shown to improve endothelial dysfunction. However, the effects of L-arginine have never been evaluated in coronavirus disease 2019 (COVID-19).
Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis / Fiorentino, G., Coppola, A., Izzo, R., Annunziata, A., Bernardo, M., Lombardi, A., Trimarco, V., Santulli, G., Trimarco, B.. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - (2021), p. 101125. [10.1016/j.eclinm.2021.101125]
Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis
Izzo, Raffaele;Bernardo, Mariano;Lombardi, Angela;Trimarco, Valentina;Santulli, Gaetano
;Trimarco, Bruno
2021
Abstract
We and others have previously demonstrated that the endothelium is a primary target of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and L-arginine has been shown to improve endothelial dysfunction. However, the effects of L-arginine have never been evaluated in coronavirus disease 2019 (COVID-19).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
